Source: Benzinga

Dyne: Dyne Therapeutics Announces Pricing of Initial Public Offering

WALTHAM, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Dyne has granted the underwriters a 30-day option to purchase up to 1,837,736 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Dyne.Dyne's common stock is expected to begin trading on the Nasdaq Global Select Market on Thursday, September 17, 2020 under the ticker symbol "DYN." The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, are expected to be approximately $233 million, excluding any exercise of the ...Full story available on Benzinga.com

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Joshua Brumm's photo - President & CEO of Dyne

President & CEO

Joshua Brumm

CEO Approval Rating

90/100

Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more